Zhejiang Starry Pharmaceutical Co., Ltd. (603520), a national high-tech enterprise specialized in R&D, manufacturing and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and fluoroquinolones series, was successfully listed on the Shanghai Stock Exchange on March 9, 2016.